Six years ago, AbbVie wrote a massive check for Allergan and loaded its balance sheet with debt that would make most CFOs lose sleep. Today, that same balance sheet shows the company technically owes more than it owns, a stockholders’ deficit of nearly $6 billion. And yet revenue is climbing at its fastest pace in years. Those two facts sitting side by side are the story.
What the numbers say
The Q2 2026 10-Q shows a business growing at double digits while carrying liabilities that exceed its assets by roughly the cost of a mid-sized pharmaceutical acquisition. The market is pricing AbbVie at a multiple, meaning the price tag per dollar of annual profit, that sits at the very top of its own decade-long range. The filed numbers show real momentum. The price assumes that momentum not only continues but accelerates. The open question is whether two drugs, Skyrizi and Rinvoq, can carry the weight the market has placed on them.
How Humira’s shadow shaped everything
For most of the 2010s, Humira, a treatment for rheumatoid arthritis and a handful of other inflammatory conditions, was the best-selling drug on earth. AbbVie built its identity around it. When U.S. patent protection ended in early 2023, cheaper biosimilar copies flooded the market and Humira’s sales began falling off a cliff. The company had seen this coming and spent years preparing, completing the Allergan acquisition in May 2020 to diversify into aesthetics and neuroscience, then adding ImmunoGen for oncology and Cerevel for neuroscience, both closed in 2024.
The strategy is now showing up in the numbers. Humira’s sales fell sharply in Q2 2026, down more than a third from the same quarter a year earlier. That sounds brutal. But Skyrizi, the next-generation immunology drug meant to replace it, generated $5.5 billion in the same quarter, growing nearly a quarter year over year. Rinvoq matched that growth rate and contributed an additional $2.5 billion. Together, those two drugs are now generating, on an annualized basis, more than Humira earned at its peak in a full year: their combined $8 billion in Q2 2026 alone puts them on a run rate well above Humira’s record $21.2 billion in 2022. The handoff, which analysts spent years worrying about, is working.
The Humira cliff is, by the filed numbers, largely behind the company. The open question is what the next growth driver looks like.
What the latest filing actually changed
The Q2 2026 earnings release carried one headline that shifted the forward picture: a definitive agreement to acquire Apogee Therapeutics for roughly $10.9 billion, a deal that closed in September 2026. Apogee brings late-stage assets aimed at dermatologic and respiratory inflammatory diseases, deepening the same immunology franchise that Skyrizi and Rinvoq already anchor. The cost of that deal trimmed the company’s full-year adjusted earnings guidance by a small but real amount, a signal that AbbVie is still willing to spend aggressively to extend its runway.
Neuroscience, the division built partly on the Allergan and Cerevel acquisitions, grew strongly in Q2 2026, reaching more than $3 billion for the quarter. Vraylar and Botox Therapeutic each crossed a billion dollars in the period. Oncology and Aesthetics, by contrast, were essentially flat. The filing is telling a story of two engines running hot and two idling.
The balance sheet remains the structural oddity. Total liabilities exceed total assets by several billion dollars, per the June 30, 2026 filing. Think of it this way: if a household owed more than everything it possessed was worth, most lenders would be nervous. AbbVie’s lenders are not, because the cash flows from Skyrizi and Rinvoq are large enough to service the debt comfortably. But it leaves no margin for a pipeline stumble.
What is compounding now
The pipeline moves from October 2026 are the most forward-looking evidence in the dossier. On October 22, AbbVie announced positive Phase 3 results for lutikizumab in hidradenitis suppurativa, a painful chronic skin condition with few good treatments. Three days earlier, on October 19, Phase 2a data for ABBV-466 in Crohn’s disease showed higher remission rates than either of the two existing drug classes it combines. Rinvoq itself has pending FDA applications for vitiligo and alopecia areata, filed in early 2026. The FDA also approved a subcutaneous, meaning self-administered at home, induction regimen for Skyrizi in Crohn’s disease on October 23, 2026, which removes a barrier that previously required patients to start treatment in a clinical setting.
Each of these moves extends the addressable market for drugs already generating billions. That is the compounding mechanism: not new molecules from scratch, but existing molecules reaching new patients. William Blair analysts noted in their Q3 2026 biopharma recap that the market has grown more selective, favoring commercial-stage companies over early-stage ones. AbbVie is squarely in the favored category. The risk is that the market already knows it.
Reading the numbers
- $16.99 billion in Q2 2026 revenue, up 10.2% year over year. Revenue is the total amount customers and insurers paid for AbbVie’s drugs in the quarter. A 10% rise means the business is growing roughly three times faster than the overall U.S. economy. Source: Q2 2026 earnings release. A household analogy: if a family’s income grew 10% in a year, they would have gone from earning $80,000 to $88,000. That is a meaningful raise.
- Stockholders’ deficit of $(5.9) billion. Stockholders’ equity, or deficit, is what would be left for owners if the company sold everything and paid every bill. A deficit means liabilities exceed assets. This is a direct consequence of the Allergan acquisition debt and subsequent deals. It does not mean the company is insolvent, because its annual cash generation is large, but it means there is no cushion if revenue falls sharply. Source: Q2 2026 10-Q.
- P/E of 119, against a decade median of 51. The P/E ratio, or price-to-earnings ratio, is the price tag the market puts on each dollar of annual profit. At 119, investors are paying more than twice the historical norm for each dollar AbbVie earns. Our data show this sits at the high end of AbbVie’s own decade range. Readers weighing that figure can compare it against the decade median of 51 and the conditions — earnings trajectory, pipeline execution — that would need to hold to sustain it. If earnings land at the filed-trend pace and the multiple drifts back toward its decade median, the math and the mood would be pointing in opposite directions.
For the standing yardsticks on Abbvie: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Abbvie.
Sources
- AbbVie 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- AbbVie Q2 2026 earnings release
- AbbVie lutikizumab Phase 3 INTREPID results, October 22, 2026
- AbbVie ABBV-466 Phase 2a data, October 19, 2026
- AbbVie completes Allergan acquisition, May 2020
- William Blair Q3 2026 US Biopharma Recap
- AbbVie 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)









